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206septum length, and rims and thickness with electronic caliper edge-
to-edge (4). Four main features were used to analyze patients: 1)
diameter of the fossa ovalis (FO); 2) presence and length of the
channel; 3) presence and degree of atrial septal aneurysm (ASA),
following the classiﬁcation of Olivares et al. (5); and 4) rim thick-
ness. We also analyzed the presence of Eustachian valve and Chiari’s
network. We considered eventual additional fenestrations within the
fossa as a functional subtype of PFO, despite that, anatomically,
they should be considered as secundum atrial septal defects.
Thus, combinations of interatrial septum anatomical features
were classiﬁed into 4 main anatomical subgroups: type 1, small
FO, no ASA, short channel, normal rims; type 2, small FO, no
ASA, long channel, normal or hypertrophic rims; type 3, large
FO, 4 to 5 ASA, short channel, normal or hypertrophic rims; and
type 4, large FO, 3 to 5 ASA, multifenestrated, short channel,
normal rims (Table 1).
FO diameter #20 mm was found to be statistically correlated
to the presence of a tunnelized PFO (r ¼ 0.91, p < 0.001),
whereas FO diameter >25 mm was associated with the presence
of ASA (r ¼ 0.88, p < 0.001) and a linear correlation between
diameter of the FO and ASA severity (the larger the fossa, the
more severe the ASA) (r ¼ 0.90, p < 0.001). Type 3 anatomical
subtype (odds ratio: 4.1 [95% conﬁdence interval: 1.5 to 8.0];
p < 0.001) and type 2 þ Eustachian valve (odds ratio: 4.3 [95%
conﬁdence interval: 1.6 to 9.0]; p < 0.001) were the strongest
predictors of recurrent ischemic events before transcatheter
closure.
Our study suggests that the anatomy of the interatrial septum
associated with R-to-L shunt is more complex than commonly
thought. The combination of the varieties of such anatomical
components identifying 4 main anatomic subtypes may help in
better clarifying the pathophysiology of paradoxical embolism,
which is unlikely to be dominated by 1 factor only, such as
ASA, PFO tunnel, or fenestrations. Intriguingly, our data
suggest that the FO diameter plays a role in determining the
presence of both tunnelized PFO, when the oval fossa is small
(<20 mm), and the presence of aneurysm, when the fossa is
large ($20 mm).
In conclusion, our study showed that in a “real-world” interatrial
septum, anatomy greatly differs among patients with R-to-L shunt.
The clinical signiﬁcance of each anatomical pattern seems different:
a device closure might be advisable in patients with high-risk
anatomical patterns whereas a medical strategy might be adopted
in the others.
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Perﬂutren-Based Echocardiographic
Contrast in Patients With
Right-to-Left Intracardiac Shunts
Use of second-generation perﬂutren-based echocardiographic
contrast agents (perﬂutren) is currently contraindicated in
patients with known right-to-left, bidirectional, or transient right-
to-left intracardiac shunts (intracardiac shunts) according to the
U.S. Food and Drug Administration. This contraindication
is primarily a result of concerns related to neurological complications
and/or systemic embolism from animal data describing entrapment
of perﬂutren lipid microspheres (>5 mm in diameter) within small
arterioles and capillaries in skeletal muscles after intra-arterial in-
jection. To date, no deﬁnitive evidence demonstrates patient safety
concerns from perﬂutren use in humans with intracardiac shunts.
We sought to evaluate the association between perﬂutren use and
adverse events in these patients.
A retrospective cohort study was performed to evaluate the as-
sociation of perﬂutren use (Deﬁnity, Lantheus Medical Imaging,
North Billerica, Massachusetts; Optison, GE Healthcare, Milwau-
kee, Wisconsin) and adverse events in patients with and without
known intracardiac shunts using the echocardiography database at
Hennepin County Medical Center (Minneapolis, Minnesota). The
study was approved by the institutional review board. Patients with
known intracardiac shunts (diagnosed using right heart contrast
[agitated saline/50% dextrose] or color ﬂow Doppler) were identi-
ﬁed from the database. Per laboratory protocol, perﬂutren was not
used in patients with cyanotic congenital heart disease. Documen-
tation of all adverse events reported by laboratory personnel within a
30-min interval after perﬂutren administration was identiﬁed. In-
dividual patient charts were reviewed to conﬁrm clinical events in all
patients who experienced adverse events. All adverse events were
further categorized as primary or secondary. Primary events were
deﬁned as neurological (stroke/transient ischemic attack) and/
or systemic embolism. Secondary events, collectively referred to
as complement activation-related pseudoallergy (CARPA), included
angioedema, bronchospasm, hypotension, hypoxemia, low back
pain, and urticaria. Fisher exact test was used to evaluate statistical
signiﬁcance.
From February 1, 1998, through November 30, 2012, 39,020
echocardiograms were performed using perﬂutren (Deﬁnity:
34,598; Optison: 4,422). An intracardiac shunt was not identiﬁed
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207in 38,602 patients (nonshunt group). An intracardiac shunt was
identiﬁed in 418 patients in the perﬂutren group (40 detected at
rest only, 128 detected following Valsalva maneuver only, 84
detected with both; 166 unknown). Patients with left-to-right
shunts only (n ¼ 63; detected by color Doppler) were excluded
from analysis. No primary adverse events occurred in the shunt
group; 1 occurred in the nonshunt group (p ¼ 0.99) (Table 1). One
secondary adverse event occurred in the shunt group, and 34 in the
nonshunt group (p ¼ 0.31). All events occurred in studies using
Deﬁnity (vs. Optison; p ¼ 0.03). Right heart contrast studies were
performed in 3,661 patients (1,432 with perﬂutren, 2,229 without
perﬂutren); intracardiac shunts were diagnosed in 839 patients
(23%).
The International Contrast Ultrasound Society recently raised
concerns about the current contraindication of perﬂutren use in
patients with known/suspected intracardiac shunts, recommending
that this contraindication be removed to improve patient care and
reduce unnecessary downstream testing (1). Agitated saline, a ﬁrst-
generation echocardiographic contrast agent (hand-agitated, with
tremendous heterogeneity in bubble size) has been widely used
during transthoracic and transesophageal echocardiograms to detect
intracardiac shunts, without regulatory oversight (1). However, the
greater diffusibility of air in the circulation, and lack of CARPA
reactions to agitated saline, probably do not allow for a direct
comparison with perﬂutren. The current observational study is the
ﬁrst to assess the use of perﬂutren in patients with intracardiac
shunts, and it demonstrates that the overall incidence of adverse
events was low in patients receiving perﬂutren. Importantly, per-
ﬂutren use in patients with these shunts (without cyanotic
congenital heart disease) was not associated with signiﬁcant adverse
neurological and/or systemic embolic events compared with use in
patients without diagnosed intracardiac shunts. Similarly, perﬂutrenTable 1. Primary and Secondary Adverse Events With Perﬂutren-Based
Echocardiographic Contrast Agent Use in Patients With and Without
Right-to-Left, Bidirectional, or Transient Right-to-Left Intracardiac Shunts
Intracardiac Shunt
Total p ValueYes No
Perﬂutren-based ECA use 418 38,602 39,020
Primary adverse events 0 1 1 0.99
Transient ischemic attack 0 1 (0.0026)
Secondary adverse events 1 34 35 0.31
Angioedema 0 1 (0.0026)
Back pain 1 (0.24) 24 (0.0622)
Bronchospasm 0 1 (0.0026)
Hypotension 0 2 (0.0052)
Hypoxemia 0 1 (0.0026)
Urticaria 0 4 (0.0104)
Vasovagal reaction 0 1 (0.0026)
Other events 0 1 1
Seizure 0 1 (0.0026)
Values are n or n (%).
ECA ¼ echocardiographic contrast agent.use was not associated with any signiﬁcant difference in secondary
adverse events (CARPA reaction) in patients with intracardiac
shunts. Of note, all CARPA reactions in our cohort occurred with
use of Deﬁnity and were consistent with previously published data
from our laboratory (2).
Study limitations include potential underestimation of adverse
event incidence due to incomplete registry ascertainment, occurrence
more than 30 min after perﬂutren administration, or occurrence in
sedated or unconscious patients. Also, relatively modest numbers of
intracardiac shunts were noted in the perﬂutren group, which was
attributable to potential selection bias and possibly the impact of the
Food and Drug Administration’s 2001 contraindication of perﬂutren
use in patients with intracardiac shunts.
The current proscription of perﬂutren is logically untenable in
clinical practice, as it is based on a “don’t ask, don’t tell” paradigm
for shunt detection in patients who are potential candidates for
receiving perﬂutren. Our data indicate that the current proscription
of perﬂutren use in patients with intracardiac shunts should be
rescinded.
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LV Noncompaction
in Ebstein’s Anomaly in Infants and
Outcomes
Left ventricular noncompaction (LVNC) is a distinct primary
myocardial disease characterized by abnormally prominent tra-
beculations in the ventricular myocardium, and is reported to
coexist with congenital heart diseases like Ebstein’s anomaly
(EA) and others (1). The clinical course of LVNC with EA is
unknown in the pediatric literature. We report a pediatric cohort
of LVNC and EA, with emphasis on the natural course and the
outcome.
We conducted a retrospective search of our institutional data-
base from 2002 to 2007 for patients with EA and LVNC. This
cohort was divided into 2 groups: group 1, patients with EA and
LVNC; and group 2, patients with EA alone. We reviewed
patients’ medical records and collected information on the age at
diagnosis, clinical presentation, electrocardiographic features,
echocardiographic severity of the LVNC based on the extent of
